LYR-220
LYR-220, Lyra’s second product candidate, is in Phase 2 development for the millions of chronic rhinosinusitis (CRS) patients who have undergone a prior sinus surgery but continue to have persistent disease.
Brent A. Senior, MD, FACS, FARS
Chief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery, UNC School of Medicine and BEACON Principal Investigator
Like LYR-210, LYR-220 is an anti-inflammatory implantable drug matrix designed to elute mometasone furoate consistently and locally for up to six months from a single administration to the inflamed mucosal tissue.
Designed for patients whose nasal cavity is enlarged due to sinus surgery, LYR-220 employs an oversized matrix. Surgical interventions do not address the underlying inflammation that is the hallmark of CRS and, as a result, symptoms often return within the first year following surgery in up to two-thirds of CRS patients.
LYR-220 is designed as a potential preferred alternative to revision sinus surgery and post-surgical medical management.
Learn MoreGET THE EXPERT PERSPECTIVE
LYR-220 in BEACON Phase 2 Study
LYR-220 in BEACON Phase 2 Study
Brent A. Senior, MD, FACS, FARSChief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery, UNC School of Medicine and BEACON Principal Investigator
LYR-220 placement compared to LYR-210
